Literature DB >> 2116086

Cerebrospinal fluid prostaglandins, interleukin 1 beta, and tumor necrosis factor in bacterial meningitis. Clinical and laboratory correlations in placebo-treated and dexamethasone-treated patients.

M M Mustafa1, O Ramilo, X Sáez-Llorens, K D Olsen, R R Magness, G H McCracken.   

Abstract

Prostaglandins (PGs), interleukin 1 beta (IL-1 beta), and tumor necrosis factor alpha (TNF alpha) are likely mediators of local inflammatory reactions. We measured PGE2, PGI2, IL-1 beta, and TNF concentrations in paired cerebrospinal fluid (CSF) samples (on admission, CSF1, and 18 to 30 hours later, CSF2) from 80 infants and children with bacterial meningitis. Forty patients received dexamethasone sodium (0.6 mg/kg per day in four intravenous doses) and 40 received an intravenous saline placebo. In CSF1, PGE2, PGI2, IL-1 beta, and TNF were detected in 90%, 56%, 98%, and 71% of specimens with mean (+/- SEM) concentrations of 462 +/- 65, 377 +/- 62, 1266 +/- 242, and 799 +/- 227 pg/mL, respectively. Concentrations of PGE2 correlated significantly with PGI2, IL-1 beta, TNF, and lactate and inversely correlated with glucose concentrations in the first CSF specimens. The PGE2, PGI2, IL-1 beta, and TNF were still detected in 40%, 18%, 97%, and 60%, respectively, of second CSF specimens obtained from placebo-treated patients. Compared with patients who had detectable PGI2 or TNF alpha concentrations in CSF2 specimens, those placebo-treated patients with no detectable PGI2 or TNF alpha activity in CSF2 had a lower incidence of neurological sequelae. Dexamethasone-treated patients had significantly lower PGE2, IL-1 beta, and lactate concentrations and higher glucose concentrations in CSF 18 to 30 hours later, shorter duration of fever, and a lower incidence of neurological sequelae than did placebo-treated patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2116086     DOI: 10.1001/archpedi.1990.02150320047024

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  23 in total

1.  Bacterial Meningitis.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-05       Impact factor: 3.598

Review 2.  Roles of proinflammatory and anti-inflammatory cytokines in pathophysiology of bacterial meningitis and effect of adjunctive therapy.

Authors:  A M van Furth; J J Roord; R van Furth
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

3.  A pilot microdialysis study in brain tumor patients to assess changes in intracerebral cytokine levels after craniotomy and in response to treatment with a targeted anti-cancer agent.

Authors:  Jana Portnow; Behnam Badie; Xueli Liu; Paul Frankel; Shu Mi; Mike Chen; Timothy W Synold
Journal:  J Neurooncol       Date:  2014-03-15       Impact factor: 4.130

Review 4.  IL-1β: an important cytokine associated with febrile seizures?

Authors:  Hong-Mei Yu; Wan-Hong Liu; Xiao-Hua He; Bi-Wen Peng
Journal:  Neurosci Bull       Date:  2012-06       Impact factor: 5.203

5.  Dexamethasone therapy for bacterial meningitis: Better never than late?

Authors:  S M King; B Law; J M Langley; H Heurter; D Bremner; E E Wang; R Gold
Journal:  Can J Infect Dis       Date:  1994-09

Review 6.  Pathogenesis and pathophysiology of bacterial meningitis.

Authors:  A R Tunkel; W M Scheld
Journal:  Clin Microbiol Rev       Date:  1993-04       Impact factor: 26.132

Review 7.  What is the role of corticosteroids in meningitis?

Authors:  D R Harvey; J P Stevens
Journal:  Drugs       Date:  1995-12       Impact factor: 9.546

Review 8.  Paediatrics--Part II.

Authors:  B L Priestley; C J Harrison; M P Gerrard; A Gibson
Journal:  Postgrad Med J       Date:  1993-04       Impact factor: 2.401

9.  IL-10 administration reduces PGE-2 levels and promotes CR3-mediated clearance of Escherichia coli K1 by phagocytes in meningitis.

Authors:  Rahul Mittal; Ignacio Gonzalez-Gomez; Ashok Panigrahy; Kerstin Goth; Richard Bonnet; Nemani V Prasadarao
Journal:  J Exp Med       Date:  2010-05-24       Impact factor: 14.307

10.  Independent down-regulation of central and peripheral tumor necrosis factor production as a result of lipopolysaccharide tolerance in mice.

Authors:  R Faggioni; G Fantuzzi; P Villa; W Buurman; L J van Tits; P Ghezzi
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.